NO20035597L - Forbedrede chelator-konjugater - Google Patents

Forbedrede chelator-konjugater

Info

Publication number
NO20035597L
NO20035597L NO20035597A NO20035597A NO20035597L NO 20035597 L NO20035597 L NO 20035597L NO 20035597 A NO20035597 A NO 20035597A NO 20035597 A NO20035597 A NO 20035597A NO 20035597 L NO20035597 L NO 20035597L
Authority
NO
Norway
Prior art keywords
chelator conjugates
improved
improved chelator
radiometal
conjugates
Prior art date
Application number
NO20035597A
Other languages
English (en)
Other versions
NO334093B1 (no
NO20035597D0 (no
Inventor
Torgrim Engell
Harry John Wadsworth
Colin Mill Archer
Original Assignee
Amersham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amersham Plc filed Critical Amersham Plc
Publication of NO20035597D0 publication Critical patent/NO20035597D0/no
Publication of NO20035597L publication Critical patent/NO20035597L/no
Publication of NO334093B1 publication Critical patent/NO334093B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32Oximes
    • C07C251/34Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/36Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0002General or multifunctional contrast agents, e.g. chelated agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
NO20035597A 2001-07-10 2003-12-16 Forbedrede chelatdannerkonjugater, radioaktive metallkomplekser, radiofarmasøytika, sett for fremstilling av radiofarmasøytika, samt bifunksjonelle chelatdannere og fremgangsmåter for fremstilling av slike NO334093B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0116815.2A GB0116815D0 (en) 2001-07-10 2001-07-10 Improved chelator conjugates
PCT/GB2002/003168 WO2003006070A2 (en) 2001-07-10 2002-07-10 Improved chelator conjugates

Publications (3)

Publication Number Publication Date
NO20035597D0 NO20035597D0 (no) 2003-12-16
NO20035597L true NO20035597L (no) 2004-03-03
NO334093B1 NO334093B1 (no) 2013-12-09

Family

ID=9918227

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20035597A NO334093B1 (no) 2001-07-10 2003-12-16 Forbedrede chelatdannerkonjugater, radioaktive metallkomplekser, radiofarmasøytika, sett for fremstilling av radiofarmasøytika, samt bifunksjonelle chelatdannere og fremgangsmåter for fremstilling av slike

Country Status (21)

Country Link
US (2) US7597875B2 (no)
EP (1) EP1404377B1 (no)
JP (1) JP5015409B2 (no)
KR (1) KR100892009B1 (no)
CN (4) CN101538313A (no)
AT (1) ATE304866T1 (no)
AU (1) AU2002317317B2 (no)
BR (1) BR0210965A (no)
CA (1) CA2450690C (no)
DE (1) DE60206272T2 (no)
DK (1) DK1404377T3 (no)
ES (1) ES2250671T3 (no)
GB (1) GB0116815D0 (no)
HK (1) HK1064585A1 (no)
HU (1) HU228850B1 (no)
IL (1) IL159388A0 (no)
MX (1) MXPA04000210A (no)
NO (1) NO334093B1 (no)
RU (1) RU2298012C2 (no)
WO (1) WO2003006070A2 (no)
ZA (1) ZA200400143B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002054088A2 (en) 2001-01-05 2002-07-11 Duke University Contrast enhancement agent for magnetic resonance imaging
NZ530156A (en) * 2001-07-10 2007-04-27 Ge Healthcare As Peptide-based compounds for targeting integrin receptors for use as diagnostic imaging agents
NO20030115D0 (no) 2003-01-09 2003-01-09 Amersham Health As Kontrastmiddel
GB0416062D0 (en) * 2004-07-19 2004-08-18 Amersham Plc Improved N4 chelator conjugates
US7785566B2 (en) 2003-11-06 2010-08-31 Ge Healthcare, Inc. Pharmaceutical compounds
WO2005049095A2 (en) 2003-11-24 2005-06-02 Amersham Health As Contrast agent imaging angiotensin ii receptors
DE602005017475D1 (de) * 2004-03-04 2009-12-17 Ge Healthcare As Konjugate von angiotensin-peptid analoga und chelatbildner für diagnose und therapie
RU2007118385A (ru) 2004-11-22 2008-12-27 Джи-И Хелткер АС (NO) Контрастные агенты для направлений доставки во внеклеточный матрикс
US20080226555A1 (en) * 2005-06-08 2008-09-18 Bengt Langstrom Method for the Use of [11C] Carbon Monoxide in Labeling Synthesis of 11C-Labelled Esters and Acids by Sensitized Photo-Induced Free Radical
GB0515974D0 (en) * 2005-08-03 2005-09-07 Ge Healthcare Ltd Compounds and imaging methods
ATE496881T1 (de) 2006-02-15 2011-02-15 Ge Healthcare As Kontrastmittel
US7943117B2 (en) * 2006-06-08 2011-05-17 Atomic Energy Council—Institute of Nuclear Research Method for testing radiochemical purity of Tc-99m-TRODAT-1
ATE471724T1 (de) * 2006-12-11 2010-07-15 Ge Healthcare As Radioaktiv markierte verbindungen auf peptidbasis und ihre verwendung
AU2009322081C1 (en) * 2008-12-02 2016-09-01 Clarity Pharmaceuticals Ltd Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals
GB0922014D0 (en) 2009-12-17 2010-02-03 Ge Healthcare Ltd Novel integrin binders
HUE050033T2 (hu) 2010-07-27 2020-11-30 Serac Healthcare Ltd Radioaktív gyógyszerkészítmények
GB201103696D0 (en) * 2011-03-04 2011-04-20 Ge Healthcare Ltd Technetium labelled peptides
GB201110767D0 (en) 2011-06-24 2011-08-10 Ge Healthcare Ltd Infection imaging
US20130195756A1 (en) * 2012-01-31 2013-08-01 General Electric Company 99mTc IMAGING AGENTS AND METHODS OF USE
KR20150140650A (ko) * 2013-02-15 2015-12-16 토마스 제퍼슨 유니버시티 종양 이미지를 위한 키트
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
US11033642B2 (en) 2014-03-19 2021-06-15 Universitat Zurich Multidentate bifunctional chelating agents for radionuclide complexation in diagnostics and therapy
WO2019217571A1 (en) * 2018-05-08 2019-11-14 University Of Miami Materials and methods for the delivery of therapeutic nucleic acids to tissues
WO2019222454A1 (en) 2018-05-16 2019-11-21 Emory University Styrylbenzothiazole derivatives and uses in imaging
CN111548275A (zh) * 2020-05-27 2020-08-18 龙曦宁(上海)医药科技有限公司 一种2-(氨基甲基)-n1,n1-二甲基丙烷-1,3-二胺三盐酸盐的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1588978A (en) * 1977-07-19 1981-05-07 Ici Ltd Coating processes
DE3930674A1 (de) * 1989-09-11 1991-03-21 Diagnostikforschung Inst Bifunktionelle chelatbildner zur komplexierung von tc- und re-isotopen, verfahren zu ihrer herstellung und darstellung von konjugaten daraus sowie deren verwendung in diagnostik und therapie
US5808091A (en) * 1991-10-29 1998-09-15 Bracco International B.V. Rhenium and technetium complexes containing a hypoxia localizing moiety
JP3083157B2 (ja) * 1993-08-04 2000-09-04 アマーシャム・インターナショナル・ピーエルシー 酸素欠乏性組織に局在する放射性金属錯体
KR960700986A (ko) * 1994-01-12 1996-02-24 네나드 토모브-그리소고노 리간드 및 이들의 금속착체(ligands and metal complexes thereof)
CA2179990A1 (en) * 1994-01-12 1995-07-20 Gary Robert Bower Biological targeting agents
WO1999060018A1 (en) * 1998-05-15 1999-11-25 Nycomed Amersham Plc Labelled glutamine and lysine analogues
US6783711B2 (en) * 2000-05-23 2004-08-31 Ge Osmonics, Inc. Process for preparing a sulfonamide polymer matrix
WO2002072718A1 (fr) * 2001-03-08 2002-09-19 Matsushita Electric Industrial Co., Ltd. Encre d'impression a jet d'encre, procede de production de l'encre, cartouche d'encre et dispositif d'impression comportant cette encre

Also Published As

Publication number Publication date
CN101537190A (zh) 2009-09-23
US7597875B2 (en) 2009-10-06
JP2005500325A (ja) 2005-01-06
MXPA04000210A (es) 2004-07-23
EP1404377B1 (en) 2005-09-21
CA2450690C (en) 2009-03-24
GB0116815D0 (en) 2001-08-29
WO2003006070A2 (en) 2003-01-23
JP5015409B2 (ja) 2012-08-29
NO334093B1 (no) 2013-12-09
RU2003137592A (ru) 2005-05-20
CN100509061C (zh) 2009-07-08
CN1527727A (zh) 2004-09-08
KR100892009B1 (ko) 2009-04-07
HUP0401265A2 (hu) 2004-09-28
ES2250671T3 (es) 2006-04-16
US20100040542A1 (en) 2010-02-18
HU228850B1 (en) 2013-06-28
CN101538313A (zh) 2009-09-23
WO2003006070A3 (en) 2003-08-21
AU2002317317B2 (en) 2005-11-17
DE60206272T2 (de) 2006-07-13
US20040258619A1 (en) 2004-12-23
DK1404377T3 (da) 2006-01-30
US8852550B2 (en) 2014-10-07
HUP0401265A3 (en) 2005-11-28
EP1404377A2 (en) 2004-04-07
HK1064585A1 (en) 2005-02-04
BR0210965A (pt) 2004-06-08
NO20035597D0 (no) 2003-12-16
ZA200400143B (en) 2004-12-29
ATE304866T1 (de) 2005-10-15
IL159388A0 (en) 2004-06-01
DE60206272D1 (de) 2005-10-27
KR20040017287A (ko) 2004-02-26
CN101607913B (zh) 2012-07-04
RU2298012C2 (ru) 2007-04-27
CA2450690A1 (en) 2003-01-23
CN101607913A (zh) 2009-12-23

Similar Documents

Publication Publication Date Title
DK1404377T3 (da) Forbedrede chelatorkonjugater
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
DK1791571T3 (da) Radiofluorinerede peptider
DE60230890D1 (de) Indolizine als kinaseproteinhemmer
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
MXPA05009682A (es) Metodos de radiofluorinacion de vectores biologicamente activos.
BRPI0411897A (pt) pirroldihidroisoquinolinas como inibidores de pde10
ECSP034600A (es) Compuestos de lactama
CL2013002895A1 (es) Compuestos derivados de 7,8-dihidro-5h-pteridin-6-ona, utiles como intermediarios en la sintesis de compuestos derivados de pteridinona (divisional de la solicitud 3123-2005).
BRPI0307702B8 (pt) formulações de solução contendo anticorpo
MA30042B1 (fr) Composes calcilytiques
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
DE60210598D1 (de) 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
DE60322562D1 (de) Konjugate von tc komplexen und zielgerichtete einheiten und ihre verwendung in nmr-diagnostik
TR199901017A2 (xx) B�cek ilac� terkibi.
DE60213084D1 (de) 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
RS20060195A (en) Imidazopyridine-derivatives as inducible no-synthase inhibitors
ATE242763T1 (de) Methoximinophenylessigsäureamide
EA200400393A1 (ru) Антитела против каспазы-8, их получение и применение
ITMI20030827A1 (it) Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
NO20021429L (no) 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner
EA200400764A1 (ru) 1,3-диарилпроп-2-ен-1-оны, композиция на их основе и применение
ES2183543T3 (es) Derivado de tiocolchicosida, su preparacion y su aplicacion en terapeutica.
HN1999000157A (es) 1,2,3 tetrahidroquinolinas 2 - sustituidas 4 - amino sustituidas.
UA115859C2 (uk) Розчинний поліпептид, який зв'язує активін а, та композиція, що його містить

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees